Bristol Myers Squibb reported a patient death following administration of its investigational autoimmune CAR-T therapy in a Phase 1 study in multiple sclerosis. The company attributed the outcome to motor symptoms that did not resolve with standard autoimmune treatments, followed by immunosuppression, then septic pneumonia. The update arrives against a backdrop of heightened scrutiny on autoimmune CAR-T programs, with other companies previously disclosing safety pauses after inflammatory events were observed. BMS also faced earlier questions that led to discussion of a summertime pause. The reported death may influence how sites monitor inflammatory toxicity and manage CAR-T related immunosuppression, while reinforcing the need for tighter patient selection and risk mitigation in autoimmune indications.